Since increased FGF3/4/19 copy number is frequently detected and highly related to the initiation and progression of many tumors including urothelial carcinoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma (Xie et al., 2020), we believe that our finding will also benefit other anti-cancer therapies targeting FGF3/4/19 variated tumors. This evidence concerns the gene FGF3 and urothelial carcinoma.